IX BIOPHARMA LTD.

(Company Registration No. 200405621W)
(Incorporated in the Republic of Singapore)

ESTABLISHMENT OF A RISK MANAGEMENT COMMITTEE

The Board of Directors (the "**Board**") of iX Biopharma Ltd. (the "**Company**" and together with its subsidiaries, the "**Group**") wishes to announce that the Board has established a Risk Management Committee ("**RMC**") with effect from 8 November 2017 to assist the Board in the risk governance of the Company.

The composition of the RMC will be as follows: -

1. Ms. Claudia Teo Kwee Yee (Chairman), Non-Executive Independent Director
2. Mr. Low Weng Keong, Non-Executive Independent Director
3. Mr. Albert Ho Shing Tung, Non-Executive Director

By Order of the Board

Lee Wei Hsiung / Wang Shin Lin, Adeline
Company Secretaries

8 November 2017

---

*This announcement has been prepared by the Company and its contents have been reviewed by the Company's sponsor, CIMB Bank Berhad, Singapore Branch (the "**Sponsor**"), for compliance with the SGX-ST Listing Manual Section B: Rules of Catalist. The Sponsor has not verified the contents of this announcement.*

This announcement has not been examined or approved by the SGX-ST. The Sponsor and the SGX-ST assume no responsibility for the contents of this announcement, including the accuracy, completeness or correctness of any of the information, statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Mr. Yee Chia Hsing, Head, Catalist. The contact particulars are 50 Raffles Place, #09-01 Singapore Land Tower, Singapore 048623, telephone: (65) 6337-5115.